Horizon Discovery
Farai Samuel Mudimbu is a Scientist at Horizon Discovery since February 2023, with a strong background in cancer research and diagnostics. Previously, as an MSc Research Candidate at the University of Leeds, Farai investigated the effects of miR-31 in sensitizing ovarian and breast cancer cell lines to chemotherapy and employed an oncolytic virus as a biological vector, successfully downregulating genes related to tumor metastasis and chemoresistance. Farai has extensive experience as a Medical Laboratory Scientist, conducting COVID-19 diagnostics at both Premium Diagnostic Centre and the National Microbiology Reference Laboratory, where process optimization significantly reduced work backlogs. Earlier roles include serving as a Graduate Research Assistant at the African Institute of Biomedical Science and Technology and a BSc Research Candidate at Swansea University, focusing on non-invasive diagnosis of esophageal cancer through mitochondrial DNA analysis. Farai holds a Master's degree in Cancer Biology and Therapy from the University of Leeds and a BSc Hons degree in Medical Genetics from Swansea University.
This person is not in any offices
Horizon Discovery
2 followers
Horizon builds human disease models and reagents derived from genetically-engineered cells that its customers use, or that are deployed on their behalf to: gain knowledge of the genetic drivers of disease; develop novel drugs or cell therapies targeted.